Oncology – Breast | Page 4 of 10 | Links Medicus Content Curation & Alerts in Medicine

Online first: #Eliminating breast #surgery for invasive #breastcancer in exceptional #responders to #neoadjuvant systemic #therapy: a multicentre, single-arm, phase 2 trial https://t.co/lxZa62zFZT pic.twitter.com/TS1dKqFhF1

— The Lancet Oncology (@TheLancetOncol) October 26, 2022

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

31 Oct, 2022 | 13:50h | UTC

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline – Annals of Oncology

Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.

31 Oct, 2022 | 13:41h | UTC

Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)

Guideline | Reporting of surgically removed lymph nodes for breast tumors.

25 Oct, 2022 | 13:20h | UTC

Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting – Archives of Pathology & Laboratory Medicine

Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.

24 Oct, 2022 | 14:00h | UTC

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study – JNCI: Journal of the National Cancer Institute

News Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press

Commentaries:

Expert reaction to study looking at menopausal hormone therapy after early-stage breast cancer, and breast cancer recurrence – Science Media Centre

Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay

Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

17 Oct, 2022 | 12:27h | UTC

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer – Annals of Oncology

Original Study: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

OS from #OlympiA now out on Annals. After 3.5y of f-up, pts receiving adjuvant olaparib derived a significant OS benefit (4y Δ 3.4%, 89.8% vs 86.4%). No increased risk of MDS/AML with olaparib. Important to test for BRCA in potentially eligible patients.https://t.co/ygkr0cOwF0 pic.twitter.com/bg4Y2yyXwZ

— Paolo Tarantino (@PTarantinoMD) October 11, 2022

Images under a Creative Commons Attribution (CC BY 4.0) license

Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

14 Oct, 2022 | 14:12h | UTC

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 – Breast Care

Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.

14 Oct, 2022 | 14:03h | UTC

Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study – Journal of Clinical Oncology

News Release: Long-term study supports link between inflammation and cognitive problems in older breast cancer survivors – University of California

Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.

13 Oct, 2022 | 13:38h | UTC

Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery – JAMA Surgery

Commentary on Twitter

https://twitter.com/JAMASurgery/status/1578052462300352520

RCT | Switch to fulvestrant and palbociclib in breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy.

7 Oct, 2022 | 14:12h | UTC

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial – The Lancet Oncology (free for a limited period)

20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.

26 Sep, 2022 | 12:00h | UTC

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial – Journal of Clinical Oncology

News Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet

Commentary on Twitter

20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA

— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022

M-A | Margin status and survival outcomes after breast cancer conservation surgery.

23 Sep, 2022 | 13:09h | UTC

Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis – The BMJ

Commentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ

News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom

Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.

7 Sep, 2022 | 12:31h | UTC

Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis – JAMA Oncology

News Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet

Commentary: Fertility Preservation Measures Do Not Appear to Increase the Risk of Breast Cancer Recurrence – The ASCO Post

Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.

31 Aug, 2022 | 11:45h | UTC

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Treatment De-Escalation With Locoregional Radiotherapy Appears Safe in cT1-2N1 Breast Cancer – Cancer Network

Commentary on Twitter

At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV

— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022